V. N. Nesterova

V. N. Nesterova

Auto-generated profile, based on publicly available information

V. N. Nesterova

N.A. Semashko Nizhny Novgorod Regional Clinical Hospital

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
EGE.I. Gusev
E.I. Gusev
MMMikhail Martynov
Mikhail Martynov
NSN.A. Shamalov
N.A. Shamalov
Elena YarovayaElena Yarovaya
Elena Yarovaya
MSM.P. Semenov
M.P. Semenov
SMSergey Markin
Sergey Markin
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение эффективности и безопасности неиммуногенной стафилокиназы (НС) в сравнении с алтеплазой (А) у пациентов с ишемическим инсультом (ИИ) в первые 4,5 ч от развития симптомов. МАТЕРИАЛ И МЕТОДЫ В открытом рандомизированном сравнительном исследовании «не меньшей эффективности» в параллельных группах НС и А приняли участие 336 пациентов (по 168 в каждой группе) в первые 4,5 ч ИИ. НС вводилась в дозе 10 мг вне зависимости от массы тела внутривенно болюсно в течение 10 с, А — болюсно-инфузионно в дозе 0,9 мг/кг (максимально 90 мг) в течение 1 ч. Первичной конечной точкой эффективности считался благоприятный исход — 0—1 балл по модифицированной шкале Рэнкина (mRS) на 90-й день после введения препаратов. Конечные точки безопасности включали смертность от всех причин на 90-й день, симптомное внутричерепное кровоизлияние и другие серьезные нежелательные явления (СНЯ). РЕЗУЛЬТАТЫ К 90-му дню заболевания первичную конечную точку в группе НС достигли 84 (50%) пациента, в группе А — 68 (41%) (p=0,10, ОШ=1,47, 95% ДИ=0,93—2,32). Разница между группами НС и А составила 9,5% (95% ДИ= –1,7—20,7), и левая граница 95% ДИ не пересекала границу «не меньшей эффективности» (p«не меньшей эффективности»<0,0001). На 90-й день умерли 17 (10%) пациентов в группе НС и 24 (14%) — в группе А (p=0,32). Частота симптомных внутричерепных кровоизлияний была несколько реже в группе НС — 5 (3%) пациентов, в группе А — 13 (8%) (p=0,087, ОШ=0,37, 95% ДИ=0,1—1,13). СНЯ в группе НС развились у 22 (13%) пациентов, в группе А — у 37 (22%) (p=0,044, ОШ=0,53, 95% ДИ=0,28—0,98). ЗАКЛЮЧЕНИЕ Результаты исследования ФРИДА являются первыми в мире по применению препарата на основе НС у пациентов с ИИ. Показано, что однократное болюсное введение НС в стандартной дозе в 10 мг вне зависимости от массы тела позволяет быстро, эффективно и безопасно проводить тромболитическую терапию у пациентов с ИИ в течение 4,5 ч от начала заболевания. В дальнейших клинических исследованиях НС планируется расширение терапевтического окна в 4,5 ч после появления симптомов у пациентов с ИИ.

30 December 2025 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
NSN A Shamalov
N A Shamalov
MMM Yu Martynov
M Yu Martynov
EGE I Gusev
E I Gusev
NMN A Marskaya
N A Marskaya
DKD R Khasanova
D R Khasanova
SMSergey Markin
Sergey Markin
Objective. To evaluate safety and efficacy outcomes of Fortelyzin in AIS patients in the FORPI (Fortelyzin Population Investigation) registry. Material and methods. Between March 2021 and October 2024 AIS patients treated with Fortelyzin were enrolled in prospective, open, monitored, observational FORPI registry. Demographics, risk factors, baseline stroke severity, defined by National Institutes of Health Stroke Scale (NIHSS), and onset to treatment time were recorded. Safety outcomes included symptomatic intracerebral haemorrhage (ICH) (according to the ECASS III and SITS-MOST criteria) within 36 h and all-cause mortality on day 90. Efficacy outcome was evaluated as a functional independence defined by modified Rankin scale (mRS score of 0—2) on day 90. Results. A total of 17 636 AIS patients were treated with Fortelyzin in 329 centres participated in the FORPI registry during the study period (median age 68 [60; 75]; 44% women; median baseline NIHSS score: 11 [8;16] points; median onset to treatment time: 2.4 [1.8; 3.1] h. 73% of patients (12947/17 636) received thrombolytic therapy in the first three hours from symptoms onset. The rate of symptomatic ICH according to the ECASS III criteria was 2% [1.8; 2.2] (356/17636), to the SITS-MOST criteria — 2% [1.8; 2.1] (330/17 636). All-cause mortality on day 90 was 9% [8.6; 9.4] (1588/17 636). The number of patients with mRS 0—2 score on day 90 was 61% [60.5; 61.9] (10799/17636). All safety and efficacy outcomes were comparable with FRIDA randomised clinical trial results. Conclusion. The presented data confirm that intravenous thrombolysis with Fortelyzin is safe and effective in routine clinical practice when used within 4.5 h of AIS symptoms onset. These findings should encourage the wider usage of thrombolytic therapy for suitable patients.

9 February 2026 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
NSN.A. Shamalov
N.A. Shamalov
MMMikhail Martynov
Mikhail Martynov
EGE.I. Gusev
E.I. Gusev
NMN.A. Marskaya
N.A. Marskaya
DKD.R. Khasanova
D.R. Khasanova
SMSergey Markin
Sergey Markin
Objective. To evaluate the safety and efficacy of Fortelyzin thrombolytic drug (non-immunogenic staphylokinase) in AIS patients in an «extended» therapeutic window from 4.5 to 24 h from symptoms’ onset based on data from the FORPI registry. Material and methods. Functional outcomes and the risk of intracranial hemorrhage after thrombolytic therapy (TLT) for acute ischemic stroke (AIS) are known to be directly dependent on the treatment time initiation. Although the most safe and effective time for TLT is the first 4.5 h from symptoms’ onset, a significant proportion of patients are hospitalized beyond this time window. The objective of this study is The FORPI registry is an open-label, prospective, non-interventional observational study of Fortelyzin in AIS patients in real-world clinical practice. A comparative analysis of safety and efficacy outcomes was conducted in groups of patients who received TLT in the first 4.5 h after symptom onset and beyond 4.5 h time window. The safety endpoints were the rate of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST criteria, as well as all-cause mortality at day 90. The efficacy endpoint was good functional recovery, defined by a modified Rankin Scale (mRS) of 0—2 score at day 90. Results. The analysis included 17.636 patients with TLT performed in the first 4.5 h after symptom onset and 358 patients with TLT performed beyond 4.5 h time window (up to 24 hours). In the group of patients with TLT performed in the interval of 4.5—24 hours, there were statistically significantly fewer people over 80 years old (8% vs 16%, p=0.001), and a lower median age (66 vs 68 years, p=0.002) compared with the group of TLT within 4.5 hours. The NIHSS median was slightly higher in the group of patients with TLT performed beyond 4.5 h time window (11 (8—16) vs 11 (8—15), p=0.036). The incidence of sICH (ECASS III) within 4.5 h was 2% compared with 2.5% beyond 4.5 h time window (p=0.454). All-cause mortality at 90 days in the main population was 9%, which is comparable with the mortality rate in the 4.5—24 h group — 7% (p=0.160). Good functional recovery (mSR 0—2) at day 90 was achieved in 61% of patients in the group who received TLT within 4.5 h, compared with 65% of patients who received TLT beyond 4.5 h time window (p=0.227). Conclusion. FORPI registry demonstrates similar data on the safety and efficacy of TLT with Fortelyzin in AIS patients both within 4.5 hours and beyond 4.5 hours from symptoms’ onset.

5 March 2026 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
NSN.A. Shamalov
N.A. Shamalov
MMMikhail Martynov
Mikhail Martynov
EGE.I. Gusev
E.I. Gusev
DKD.R. Khasanova
D.R. Khasanova
VNV.N. Nesterova
V.N. Nesterova
SMSergey Markin
Sergey Markin
Objective. To evaluate the safety and efficacy of Fortelyzin during bridging therapy (thrombolysis followed by thrombectomy) in real-world clinical practice using data from the FORPI registry. Material and methods. The FORPI registry is an open-label, prospective, non-interventional observational study of Fortelyzin in patients with acute ischemic stroke. In this article we analyzed the safety and efficacy of Fortelyzin in patients undergoing thrombolysis followed by thrombectomy. The safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST definitions, as well as all-cause mortality on day 90. The efficacy outcome was a good functional recovery, defined by mRS score of 0—2 on day 90. Results. The analysis included 1116 patients undergoing thrombolysis followed by thrombectomy who were enrolled in a registry at 120 medical cites in 55 regions of the Russian Federation. The median patient age was 69 (61—77) years. The median NIHSS score at admission was 15 (12—19) points. The sICH rate according to ECASS III was 13% (144/1116), and according to SITS-MOST was 9% (98/1116). In hospital mortality rate was 27% (301/1116 patients). All-cause mortality on day 90 was 29% (322/1116 patients). Good functional outcome (mRS 0—2) on day 90 was achieved in 38% (422/1116) of patients. Conclusion. This study demonstrates the safety and efficacy of Fortelizin in bridging therapy of acute ischemic stroke in real-world clinical practice.

15 April 2026 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
NSN.A. Shamalov
N.A. Shamalov
MMMikhail Martynov
Mikhail Martynov
NMN.A. Marskaya
N.A. Marskaya
DKD.R. Khasanova
D.R. Khasanova
Elena YarovayaElena Yarovaya
Elena Yarovaya
EGE.I. Gusev
E.I. Gusev
Objective. The aim of this study was to evaluate the safety and efficacy of Fortelyzin in patients ≥80 years with ischemic stroke (IS) in real-world clinical practice using data from the FORPI registry. Material and Methods. Fortelyzin (INN/chemical name — a recombinant protein containing the amino acid sequence of staphylokinase, SuperGene LLC, Moscow, Russia) is a thrombolytic used for acute IS treatment within the first 4.5 hours of symptom onset. The FORPI registry is an open-label, prospective, non-interventional, observational study of Fortelyzin in patients with IS. We analyzed the safety and efficacy outcomes in patients ≥80 years compared with patients <80 years. Safety outcomes included the incidence of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST definitions, as well as all-cause mortality on day 90. The efficacy outcome was a good functional recovery, defined by an mRS score of 0—2 on day 90. Results. 2649 (15%) patients were ≥80 years, and 14 987 (85%) patients were <80 years. The median age in the group of patients ≥80 years was 83 (82—86) years. Patients ≥80 years were characterized by a more complicated medical history and a higher median of NIHSS and mRS score. The sICH rate according to ECASS III definition in patients ≥80 years old was 4.0%, in patients <80 years old — 1.7% (OR 2.42 (1.90—3.07), p<0.001), according to SITS-MOST definition — 3.2% and 1.6%, respectively (OR 2.03 (1.56—2.61), p<0.001); in-hospital all-cause mortality was 17% and 7% (OR 2.76 (2.44—3.11, p<0.001), all-cause mortality on day 90 was 19% and 7% (OR 3.00 (2.67—3.37, p<0.001), respectively. Good functional recovery (mRS 0—2 score) on day 90 was achieved in 43% of patients ≥80 years and 64% in patients <80 years of age (OR 0.42 (0.38—0.46, p<0.001)). Conclusion. FORPI study showed that although the risk of sICH with Fortelyzin is higher in patients ≥80 years than in patients <80 years, it remains low, suggesting that thrombolytic therapy is safe and necessary in these patients.

17 February 2025 in Neurology, Neuropsychiatry, Psychosomatics
Verified
Journal Article
Open access
PDF file
NSN. A. Shamalov
N. A. Shamalov
DKD. R. Khasanova
D. R. Khasanova
SMS. V. Marchenko
S. V. Marchenko
MSM. A. Soldatov
M. A. Soldatov
TAT. P Alekseeva
T. P Alekseeva
NMN. A. Marskaya
N. A. Marskaya
Thrombolytic therapy (TLT) of ischemic stroke (IS) with alteplase within the first 4.5 hours from the onset of symptoms is the most effective and proven method of treatment.Objective: to evaluate the safety and efficacy of TLT with Revelisa (alteplase) in IS in real-world clinical practice.Material and methods. The results of TLT with Revelisa were analyzed in 1181 patients with IS: 616 (52.2%) women and 565 (47.8%) men (mean age 68.28±12.56 years), of which 140 (11.9%) with staged reperfusion. The mean time from disease onset to TLT was 2.58±0.83 hours. The Heidelberg classification was used to assess hemorrhages during neuroimaging. Symptomatic hemorrhagic transformation (HT) was defined according to ECASS III criteria. The study group was characterized by high comorbidity: arterial hypertension (96.9%), ischemic heart disease (56.7%), chronic heart failure (55.8%) and cardiac arrhythmias (33.3%) were most common; diabetes mellitus was present in 23% of patients. IS occurred repeatedly in 15.4% of cases.Results. An improvement of 4 points or more on the NIHSS scale one day after TLT was observed in 41% of patients. The dynamics of the decrease in neurological symptoms one day later and at the time of discharge were statistically significant (p<0.001). The hospital mortality rate for the entire group was 8%, for the TLT group without endovascular intervention 5.6%. Twenty-nine patients (2.46%) had symptomatic HT, 14 of whom underwent endovascular intervention. The proportion of patients with a favorable clinical outcome (0–2 points on the modified Rankin scale) at discharge and at day 90 was 50.1% and 65.5%, respectively.Conclusion. The results of the PRIMA study confirm the high level of efficacy and safety of Revelisa in patients with IS, including during staged reperfusion. The data obtained are consistent with the published registry studies on alteplase in IS.